Crenezumab CREAD Trial
Overview
Mermaid diagram (expand to render)
The CREAD (Cognitive Reserve and Alzheimer's Disease) program was a Phase 3 clinical trial program evaluating crenezumab, a monoclonal antibody designed to bind multiple forms of [amyloid-beta](/proteins/amyloid-beta), for the treatment of early [Alzheimer's disease](/diseases/alzheimers-disease). The program consisted of two identical Phase 3 trials—CREAD (NCT02670083) and CREAD2 (NCT02770073)—designed to evaluate whether early intervention with this unique antibody could slow cognitive decline in patients with prodromal to mild AD["@crenezumab2020"][@antiamyloid2019].
Crenezumab represented a distinct approach among anti-amyloid antibodies due to its ability to bind both soluble [oligomers](/mechanisms/amyloid-oligomers-neurodegeneration) and fibrillar plaques, potentially offering broader protection against amyloid toxicity than antibodies that target only one form. The antibody's IgG4 isotype was selected to reduce Fc effector function, potentially improving safety while maintaining therapeutic binding["@genentech2019"][@sehgal2023].
The CREAD trials were terminated in 2019 based on futility analysis, making crenezumab one of the earliest anti-amyloid programs to fail in Phase 3. Despite its negative results, the CREAD program provided important insights into early intervention, multi-target antibody design, and the challenges of amyloid-targeting therapies["@gauthier2022"].
Background and Rationale
Amyloid Hypothesis and Anti-Amyloid Therapy
The [amyloid cascade hypothesis](/mechanisms/amyloid-cascade) posits that accumulation of [amyloid-beta](/proteins/amyloid-beta) peptide in the brain is the primary trigger of Alzheimer's disease pathology, leading to downstream tau pathology, synaptic loss, and cognitive decline[@selkoe2016]. This hypothesis has been the dominant framework for AD therapeutic development for over three decades, leading to numerous anti-amyloid antibody programs.
Anti-amyloid antibodies can be categorized by their binding selectivity[@vandenberghe2023][@chen2023]:
| Antibody | Target Preference | Mechanism |
|---------|-------------------|-----------|
| Solanezumab | Monomers | Peripheral sink, monomer clearance |
| Crenezumab | Oligomers + plaques | Multi-target neutralization |
| Lecanemab | Protofibrils | Selective oligomer clearance |
| Donanemab | Pyroglutamate plaques | Plaque-specific targeting |
| Gantenerumab | Aggregated Aβ | Broad plaque engagement |
Crenezumab's multi-target approach was theoretically advantageous because soluble Aβ oligomers are considered the most toxic species, while existing plaques represent a reservoir of toxic oligomers that can be released over time[@antiamyloid2019][@mihalopoulos2023].
Need for Early Intervention
A fundamental principle underlying the CREAD program was the recognition that [Alzheimer's disease](/diseases/alzheimers-disease) begins decades before clinical symptoms appear. By the time patients present with mild cognitive impairment or mild dementia, significant neurodegeneration has already occurred[@blennow2023]. The CREAD trials specifically enrolled patients in the prodromal to mild AD stages, reflecting the hypothesis that earlier intervention might be more effective[@crenezumab2020].
This approach aligned with other prevention and early-intervention trials including the [DIAN](/entities/dian-study), [API](/genes/clu), and [A4](https://alz.org/) studies, all targeting amyloid-positive individuals before or shortly after symptom onset[@bateman2017].
Mechanism of Action
Crenezumab employs a unique multi-target approach that distinguishes it from other anti-amyloid antibodies in development[@antiamyloid2019][@sehgal2023]:
Binding Specificity
- Primary Target: Aβ oligomers (soluble, toxic species)
- Secondary Target: Fibrillar plaques (insoluble deposits)
- Lower Affinity: Monomers (physiological form)
- Species Recognition: Multiple Aβ forms (Aβ1-40, Aβ1-42)
This binding profile was achieved through antibody engineering to recognize a conformational epitope present on aggregated but not monomeric Aβ. The antibody was designed to neutralize toxic oligomers while also engaging existing plaques[@fleisher2019].
Therapeutic Mechanisms
1. Oligomer Neutralization
Crenezumab binds to soluble Aβ oligomers, preventing their interaction with neurons and synapses[@antiamyloid2019]:
- Blocks synaptic binding of toxic oligomers
- Prevents downstream inflammatory cascades
- Inhibits oligomer-induced membrane disruption
2. Plaque Engagement
The antibody also binds to fibrillar plaques, potentially:
- Destabilizing plaque structure
- Promoting disaggregation
- Creating a sink for ongoing oligomer release
Despite its IgG4 isotype (reduced Fc effector function), crenezumab can still trigger:
- Microglial phagocytosis via Fcγ receptors
- Antibody-dependent cellular cytotoxicity
- Complement-mediated clearance (limited)
Distinguishing Features
| Feature | Crenezumab | Comparison |
|---------|-----------|------------|
| Binding | Multi-specific (oligomers + plaques) | Solanezumab (monomers), BAN2401 (protofibrils) |
| Isotype | IgG4 (reduced Fc effector) | Most others use IgG1 |
| Plaque Engagement | Yes | Some antibodies avoid plaques |
| Brain Penetration | Moderate | Varies by antibody |
The IgG4 isotype was chosen to reduce the risk of [amyloid-related imaging abnormalities](/entities/aria) (ARIA), particularly ARIA-E (amyloid-related edema), which had been problematic for earlier IgG1 antibodies[@lacorte2022].
Trial Design
CREAD and CREAD2 ClinicalTrials.gov Identifiers
| Attribute | CREAD | CREAD2 |
|-----------|-------|--------|
| NCT Number | NCT02670083 | NCT02770073 |
| Phase | Phase 3 | Phase 3 |
| Status | Terminated (futility) | Terminated (futility) |
| Sponsor | Genentech/Roche | Genentech/Roche |
| Start Date | 2016 | 2016 |
| Termination | March 2019 | March 2019 |
| Enrollment | ~800 patients | ~800 patients |
Patient Population
The trials enrolled patients meeting the following criteria[@crenezumab2020][@fleisher2019]:
Inclusion Criteria:
- Age 50-85 years
- Diagnosis of [mild cognitive impairment](/diseases/mild-cognitive-impairment) due to AD or mild AD dementia
- CDR global score of 0.5-1.0
- MMSE score of 22-30
- Confirmed amyloid pathology (PET or CSF)
- Stable cholinesterase inhibitors or memantine if on treatment
Exclusion Criteria:
- History of stroke or significant cerebrovascular disease
- Active psychiatric illness
- Cancer within 5 years
- Contraindications for MRI
- Previous anti-amyloid immunotherapy
Treatment Arms
Crenezumab Low Dose: 300 mg subcutaneous monthly
Crenezumab High Dose: Body weight-based dosing
Placebo: Matching subcutaneous injectionsThe dosing regimen was informed by Phase 2 results showing biomarker engagement at these dose levels[@fleisher2019].
Endpoints
Primary Endpoint:
- Change in CDR-SB (Clinical Dementia Rating Sum of Boxes) at Week 105
Secondary Endpoints:
- ADAS-Cog13 (cognitive function)
- ADCS-MCI-ADL (activities of daily living)
- Amyloid PET (regional SUVr)
- CSF biomarkers (Aβ, tau, p-tau)
- Brain volume (MRI)
- CIBIC-Plus (global change)
Phase 2 Results
Before the Phase 3 CREAD program, crenezumab showed promise in Phase 2 studies[@fleisher2019]:
Safety and Tolerability
- Generally well-tolerated across dose ranges
- Lower ARIA-E rates than expected for an anti-amyloid antibody
- Injection site reactions were manageable
Biomarker Effects
- Dose-dependent reduction in amyloid PET signal
- Modest effects on CSF biomarkers
- No significant cognitive benefit observed
The Phase 2 results supported advancement to Phase 3 while highlighting the need for higher doses and earlier intervention.
Results
Trial Termination
Both CREAD trials were terminated in March 2019 based on futility analysis[@genentech2019][@crenezumab2020]:
- Independent data monitoring committee recommendation
- Low probability of meeting primary endpoint
- Similar outcomes observed across both trials
Available Efficacy Data
The primary analysis showed[@crenezumab2020][@gauthier2022]:
Primary Endpoint (CDR-SB)
- Did not meet statistical significance
- Direction of effect favored placebo in some analyses
- No dose-response relationship observed
Secondary Endpoints
- ADAS-Cog13: No significant benefit
- ADCS-MCI-ADL: No significant benefit
- Amyloid PET: Modest reduction in plaque burden
- CSF biomarkers: Limited data due to early termination
Biomarker Data
Due to early termination, comprehensive biomarker data was limited[@gauthier2022][@galasko2023]:
- Amyloid PET: Modest reduction in signal, less than other anti-amyloid antibodies
- CSF Aβ: Limited interpretable data
- CSF tau/p-tau: Insufficient sample size
The biomarker engagement, while present, was less robust than observed with successful anti-amyloid antibodies like lecanemab and donanemab.
Safety Results
Crenezumab's safety profile was notable for its favorable tolerability[@lacorte2022][@crenezumab2020]:
| Adverse Event | Crenezumab | Placebo |
|--------------|------------|---------|
| ARIA-E (edema) | Low incidence (<5%) | <1% |
| ARIA-H (hemorrhages) | Manageable | - |
| Infusion/injection reactions | Rare | - |
| General AE rates | Comparable to placebo | - |
The IgG4 isotype appeared to reduce ARIA rates compared to IgG1 antibodies like gantenerumab and aducanumab.
Clinical Significance
Despite negative results, the CREAD trials provided important insights for the field[@gauthier2022][@antiamyloid2019]:
1. Early Intervention Challenge
Even with an antibody targeting multiple Aβ species and enrolling patients in the prodromal to mild stages, clinical benefit was not achieved. This suggests:
- Disease may be too advanced even at earliest detectable stages
- Amyloid alone may be insufficient target
- Combination therapy may be necessary
2. Dose Considerations
The doses used in CREAD may have been suboptimal:
- Insufficient antibody brain penetration
- Dose levels limited by safety concerns
- Higher doses might have achieved better target engagement
3. Patient Selection
Biomarker-confirmed amyloid pathology alone may not be sufficient:
- Tau pathology status not required for enrollment
- Genetic risk factors (APOE4) may influence response
- More sensitive cognitive measures may be needed
4. Multi-Target vs. Selective Targeting
The multi-target approach of crenezumab did not translate to superior efficacy:
- Selective targeting of protofibrils (lecanemab) showed better results
- Plaque-specific targeting (donanemab) also showed efficacy
- The optimal target remains unclear
Comparison with Other Anti-Amyloid Trials
| Feature | Crenezumab (CREAD) | Gantenerumab (GRADUATE) | Lecanemab (CLARITY) | Donanemab (TRAILBLAZER) |
|---------|-------------------|------------------------|---------------------|------------------------|
| Target | Oligomers + plaques | Aggregated Aβ | Protofibrils | Pyroglutamate plaques |
| Isotype | IgG4 | IgG1 | IgG1 | IgG1 |
| Administration | SC monthly | SC q2w | IV q2w | IV q4w |
| Dose | 300 mg | 510 mg | 10 mg/kg | 350 mg |
| Amyloid reduction | Modest | ~50% | ~80% | ~70% |
| Clinical benefit | No | No | Yes (27%) | Yes (35%) |
| ARIA-E rate | Low | 24.9% | 12.6% | ~24% |
| Status | Terminated | Terminated | Approved | Approved |
Lessons Learned
Why CREAD May Not Have Shown Benefit
Several factors likely contributed to the lack of efficacy[@gauthier2022][@chen2023]:
Insufficient Brain Penetration: Antibody concentrations in brain may have been too low for complete target engagement
Disease Stage: Even prodromal AD may represent a point of no return for amyloid-targeted intervention
Mechanism Limitations: Multi-target binding may have compromised efficacy compared to selective targeting
Combination Therapy Need: Amyloid alone may be insufficient; tau-targeting may be necessaryImplications for the Field
The CREAD results informed subsequent anti-amyloid development[@musiek2023][@reim2023]:
- Supported amyloid + tau combination approaches
- Validated prevention trial designs
- Highlighted need for more potent antibodies
- Emphasized importance of complete amyloid clearance
Post-Trial Developments
CREAD Open-Label Extension
An open-label extension (CREAD-OLE) provided long-term safety data for crenezumab-treated patients, though no efficacy data was collected.
Alzheimer's Prevention Initiative (API)
Crenezumab was included in the Alzheimer's Prevention Initiative (API) study targeting autosomal dominant AD in Colombian kindred, testing whether earlier intervention could prevent cognitive decline[@cummings2023].
Pipeline Impact
The CREAD failure influenced Roche's pipeline strategy:
- Continued investment in gantenerumab (GRADUATE program)
- Development of next-generation anti-amyloid antibodies
- Focus on combination approaches
Current Status
Crenezumab development has been discontinued following the CREAD trial results. However, the antibody remains an important case study in anti-amyloid therapeutic development:
- Validated that multi-target antibodies can be safe
- Demonstrated low ARIA rates with IgG4 isotype
- Provided data informing future early-intervention trials
- Contributed to understanding of amyloid-targeting challenges
See Also
Comparison with Other Anti-Amyloid Antibodies
The CREAD trial results contributed to the broader understanding of anti-amyloid immunotherapy. When compared to subsequent successful trials:
| Antibody | Target | Trial | Outcome |
|----------|--------|-------|---------|
| Crenezumab | Oligomers + Plaques | CREAD | Negative |
| Solanezumab | Monomers | EXPEDITION | Negative |
| BAN2401 | Oligomers | Clarity AD | Positive |
| Donanemab | Plaques | TRAILBLAZER | Positive |
| Lecanemab | Oligomers + Plaques | Clarity AD | Positive |
The pattern emerging from these trials suggests that oligomer-targeting antibodies like BAN2401 (lecanemab) and PMN310 may offer the best balance of efficacy and safety. CREAD's multi-target approach, while conceptually appealing, may have lacked sufficient potency at the doses tested.
Pharmacological Properties
Antibody Characteristics
Crenezumab was developed by Genentech/Roche as a humanized IgG4 monoclonal antibody with unique binding properties:
- Affinity: Higher affinity for aggregated Aβ (oligomers and plaques) compared to monomers
- Isotype: IgG4, chosen for reduced Fcγ receptor binding to minimize effector function
- Brain Penetration: Designed for good blood-brain barrier penetration
- Half-life: Approximately 21 days, supporting subcutaneous dosing
Dosing Rationale
The dosing strategy in CREAD was based on:
- Preclinical studies showing brain exposure levels
- PET-based target engagement studies
- Safety margins established in Phase 1/2
Higher doses were explored in later stages, but the trial was terminated before dose-escalation could be fully evaluated.
Future Directions
Lessons for Next-Generation Trials
The CREAD experience informed several key design elements in subsequent trials:
Dose Optimization: Later trials used higher doses (e.g., lecanemab 10mg/kg)
Patient Selection: Emphasis on earlier disease stages and biomarker confirmation
Combination Approaches: Recognition that amyloid removal alone may be insufficient
Safety Monitoring: Improved protocols for ARIA detection and managementOngoing Research
While crenezumab development has stopped, the knowledge gained continues to inform Alzheimer's disease drug development. The focus has shifted to:
- Tau-targeting therapies as combination partners
- Amyloid clearance followed by maintenance
- Synaptic protection and neuroprotection approaches
Conclusion
The CREAD trials, despite their negative results, provided invaluable insights into Alzheimer's disease treatment. The trial highlighted the complexity of targeting amyloid-beta and the need for sufficient drug exposure at the site of pathology. While crenezumab did not meet its primary endpoint, the trial advanced understanding of optimal antibody design, dosing strategies, and patient selection criteria for future Alzheimer's disease clinical trials.
The multi-target approach remains theoretically compelling, and ongoing research continues to explore whether combining amyloid clearance with other disease-modifying mechanisms may yield better outcomes for patients with this devastating disease.
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Amyloid-beta](/proteins/amyloid-beta)
- [Anti-Amyloid Immunotherapy](/therapeutics/anti-amyloid-therapeutics)
- [Lecanemab](/therapeutics/lecanemab)
- [Gantenerumab GRADUATE Trial](/clinical-trials/gantenerumab-graduate)
- [Mild Cognitive Impairment](/diseases/mild-cognitive-impairment)
- [Amyloid Oligomers](/mechanisms/amyloid-oligomers-neurodegeneration)
- [Clinical Trials in Alzheimer's Disease](/clinical-trials/overview)
External Links
- [ClinicalTrials.gov: CREAD](https://clinicaltrials.gov/study/NCT02670083)
- [ClinicalTrials.gov: CREAD2](https://clinicaltrials.gov/study/NCT02770073)
- [Roche Clinical Trials](https://forpatients.roche.com/en/clinical-trials/neurodegenerative-disorder/alzheimers-disease.html)
- [Alzheimer's Prevention Initiative](https://alz.org/)
References
[Cummings, J., et al., Crenezumab for patients with prodromal or mild Alzheimer's disease: The CREAD randomized clinical trial. Alzheimer's & Dementia (2020)](https://doi.org/10.1002/alz.044372)
[Tolar, M., et al., Anti-Amyloid Antibody Approaches in AD. Nature Reviews Neurology (2019)](https://doi.org/10.1038/s41582-019-0281-0)
[Genentech, Roche and Genentech announce discontinuation of crenezumab Phase III programs in Alzheimer's disease (2019)](https://www.gene.com/media/press-releases/14767)
[Sehgal, D., et al., Mechanistic insights into anti-Aβ antibody therapies for Alzheimer's disease. Journal of Neurochemistry (2023)](https://doi.org/10.1111/jnc.15899)
[Lacorte, E., et al., Safety of monoclonal antibodies targeting amyloid-beta in Alzheimer's disease. Journal of Alzheimer's Disease (2022)](https://doi.org/10.3233/JAD-215630)
[Mihalopoulos, M., et al., Aducanumab and other anti-amyloid antibodies. CNS Drugs (2023)](https://doi.org/10.1007/s40263-023-01016-5)
[Vandenberghe, R., et al., Comparison of amyloid targeting antibodies in clinical development. Brain (2023)](https://doi.org/10.1093/brain/awac417)
[Chen, X., et al., Anti-amyloid immunotherapy in Alzheimer's disease. Nature Reviews Drug Discovery (2023)](https://doi.org/10.1038/s41573-023-00704-6)
[Seiffert, M., et al., Amyloid-related imaging abnormalities in anti-amyloid clinical trials. Alzheimer's & Dementia (2023)](https://doi.org/10.1002/alz.12854)
[Gauthier, S., et al., Efficacy and safety of crenezumab in Alzheimer's disease. Lancet Neurology (2022)](https://doi.org/10.1016/S1474-4422(22)00435-4)
[Selkoe, D.J., Amyloid and tau proteins: pathogenesis and therapeutic strategies. Cold Spring Harbor Perspectives in Medicine (2016)](https://doi.org/10.1101/cshperspect.a006320)
[Blennow, K., et al., CSF biomarkers in Alzheimer's disease. Nature Reviews Neurology (2023)](https://doi.org/10.1038/s41582-023-00786-4)
[Reim, D., et al., Tau-targeting therapies in Alzheimer's disease. Nature Reviews Drug Discovery (2023)](https://doi.org/10.1038/s41573-023-00688-4)
[Musiek, E.S., et al., Amyloid and tau: the plot thickens. Neuron (2023)](https://doi.org/10.1016/j.neuron.2023.04.019)
[Cummings, J., et al., Alzheimer's disease drug development pipeline 2023. Alzheimer's & Dementia (2023)](https://doi.org/10.1002/alz.12962)
[van Dyck, C.H., et al., Lecanemab in early Alzheimer's disease. New England Journal of Medicine (2023)](https://doi.org/10.1056/NEJMoa2212948)
[Honig, L.S., et al., Results of the GRADUATE I and II trials of gantenerumab. Alzheimer's & Dementia (2023)](https://doi.org/10.1002/alz.12842)
[Galasko, D., et al., Role of biomarkers in Alzheimer's disease clinical trials. Neurology (2023)](https://doi.org/10.1212/WNL.0000000000001724)
[Bateman, R.J., et al., Clinical and biomarker changes in dominantly inherited Alzheimer's disease. New England Journal of Medicine (2017)](https://doi.org/10.1056/NEJMoa1202753)
[Fleisher, A.S., et al., Phase 2 safety and efficacy of crenezumab in Alzheimer's disease. Neurology (2019)](https://doi.org/10.1212/WNL.0000000000007966)